Clinical Trial Update: Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A phase 2 trial of Motexafin Gadolinium in chronic lymphocytic leukemia or small lymphocytic lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Motexafin Gadolinium (motexafin gadolinium)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED